Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnersh...( Researchers gain access to Sigma-...)

Researchers gain access to Sigma-Aldrich's leading MISSION(TM) shRNA

libraries

ST. LOUIS, Oct. 15 /PRNewswire/ -- Sigma-Aldrich (Nasdaq: SIAL), a leading life science company and member of The RNAi Consortium (TRC), proudly welcomes the Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program (http://sigma-aldrich.com/rpp). The RNAi Partnership Program provides new members with access to cutting-edge products in Sigma-Aldrich's functional genomics portfolio, including shRNA libraries developed by TRC targeting more than 15,000 human genes and 15,000 mouse genes (http://sigma-aldrich.com/shrna).

"We are excited to become a member of the RNAi Partnership Program and we look forward to productive collaborations with our colleagues at Sigma- Aldrich," said Dr. Hakim Djaballah, Director of the High Throughput Screening Core Facility. "Many of our researchers are interested in targeted gene knockdown on an individual or gene-focused basis, as well as a genome-wide scale for which we are fully equipped. Access to Sigma-Aldrich's MISSION shRNA libraries will greatly enhance our current gene scanning capabilities and will enable us to discover and validate cancer-causing genes and pathways which will hopefully lead to novel approaches to therapeutic intervention for cancer patients."

Through the RNAi Partnership Program, Sigma-Aldrich aims to establish collaborations with select academic institutions. The company advances functional genomics research by aiding academic researchers with early exposure to emerging new techniques, a broad portfolio of intellectual pro
'/>"/>